SCPH.Scpharmaceuticals INC

10-Q: scPharmaceuticals Reports Increased Revenue in Q1 2025, Expands FUROSCIX Indication

Sentiment:

Quarterly Report

📋All filings for Scpharmaceuticals INC
🔒Login to Follow

scPharmaceuticals Inc. announces increased product revenue and the approval of FUROSCIX for treating edema in patients with chronic kidney disease in its Q1 2025 report.

Summary

  • scPharmaceuticals Inc. reported its Q1 2025 financial results, showing increased product revenue compared to Q1 2024.
  • The company's net product revenues for Q1 2025 were $11.8 million, up from $6.1 million in Q1 2024.
  • The increase in revenue is attributed to higher demand for FUROSCIX.
  • The company's net loss for Q1 2025 was $19.7 million, compared to a net loss of $14.1 million in Q1 2024.
  • Research and development expenses increased to $4.6 million from $2.7 million year-over-year.
  • Selling, general, and administrative expenses also increased to $21.4 million from $17.4 million year-over-year.
  • The company's cash and cash equivalents stood at $57.5 million as of March 31, 2025.
  • scPharmaceuticals received FDA approval to expand the FUROSCIX indication to include the treatment of edema due to fluid overload in adult patients with chronic kidney disease (CKD).
  • The company commenced the product launch for the expanded indication in April 2025.
  • The company is targeting a sNDA submission for the autoinjector in the third quarter of 2025.
  • Approximately 14,000 FUROSCIX doses were filled in the quarter ended March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is experiencing increased revenue and has received FDA approval for an expanded indication, it is also incurring significant losses and increasing operating expenses. The future outlook is uncertain, depending on the success of FUROSCIX commercialization and the company's ability to secure additional funding.

Positives

  • Product revenue increased significantly due to higher demand for FUROSCIX.
  • FDA approval for expanded indication of FUROSCIX to include CKD patients.
  • Development of an autoinjector could reduce manufacturing costs and offer environmental advantages.
  • The company estimates a large addressable market for FUROSCIX in the US.
  • The company's existing cash and cash equivalents, including the available proceeds from the Credit Agreement and the Revenue Purchase and Sale Agreement, will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued.

Negatives

  • The company experienced a net loss of $19.7 million in Q1 2025, which is higher than the $14.1 million loss in Q1 2024.
  • Operating expenses, including research and development and selling, general, and administrative costs, increased significantly.
  • The company has an accumulated deficit of approximately $ 386.2 million.

Risks

  • The company expects to continue to incur net losses for the foreseeable future.
  • Future capital requirements will depend on various factors, and additional financing may not be available on acceptable terms or at all.
  • The company's financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of FUROSCIX, the scope and progress of our research and development efforts and timing of certain expenses.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it supports the commercialization of FUROSCIX and continues research and development efforts. The company plans to continue to fund our operations through cash and cash equivalents on hand. Additionally, we expect to have access to funds pursuant to our at-the-market offering program with Cowen and Company, LLC, or we could otherwise seek additional funding through a combination of public or private equity offerings, or debt financings, if we believe additional resources are needed.

Management Comments

  • We are a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations while developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs.

Industry Context

scPharmaceuticals is operating in the cardiorenal healthcare space, focusing on therapies for subcutaneous administration as an alternative to IV delivery. This approach aims to reduce healthcare costs and improve patient convenience. The company's focus on heart failure and chronic kidney disease aligns with the growing need for innovative treatments in these areas.

Comparison to Industry Standards

  • FUROSCIX is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home.
  • IV equivalence was established in a clinical study in which FUROSCIX demonstrated 99.6% bioavailability (90% CI: 94.8%-104.8%) and 8-hour urine output of 2.7 L which was similar to subjects receiving intravenous furosemide.
  • At a price of approximately $947 per dose, we estimate the average cost of treatment with FUROSCIX for each episode to be approximately $5,685, which can be significantly lower than the cost of a single hospitalization for worsening heart failure.

Stakeholder Impact

  • Shareholders: Potential for long-term growth and value creation, but also risk of dilution and financial losses.
  • Employees: Job security and potential for career advancement within a growing company.
  • Customers (Patients): Access to a novel treatment option for heart failure and chronic kidney disease.
  • Suppliers: Increased demand for FUROSCIX may lead to increased business opportunities.
  • Creditors: Repayment of debt obligations and potential for future financing opportunities.

Next Steps

  • Continue commercialization efforts for FUROSCIX in the United States.
  • Pursue sNDA submission for the autoinjector in Q3 2025.
  • Advance pipeline programs beyond FUROSCIX.
  • Continue research and development activities.
  • Seek additional research programs and product candidates.
  • Initiate preclinical testing and clinical trials for any product candidates identified and developed.
  • Maintain, expand and protect intellectual property portfolio.

Key Dates

DateDescription
February 19, 2013scPharmaceuticals LLC was formed as a limited liability company under the laws of the State of Delaware.
March 24, 2014scPharmaceuticals LLC was converted to a Delaware corporation and changed its name to scPharmaceuticals Inc.
October 13, 2022The Company entered into a Credit Agreement and Guaranty (the 'Oaktree Agreement').
October 7, 2022FUROSCIX was approved by the FDA.
February 1, 2023The Board of Directors of the Company adopted the 2023 Employment Inducement Award Plan (the 'Inducement Plan').
First Quarter 2023The commercial launch of FUROSCIX for congestion in patients with chronic heart failure commenced.
February 2024The company submitted an investigational new drug application (IND).
April 2024The company initiated a pharmacokinetic/pharmacodynamic PK/PD study.
May 2024The company completed enrollment in the PK/PD study.
Early May 2024The company submitted a supplemental New Drug Application (sNDA), seeking to expand the indication of FUROSCIX to include the treatment of edema due to fluid overload in adult patients with chronic kidney disease (CKD).
June 2024Another U.S. patent was granted, further strengthening our coverage of concentrated formulations of furosemide.
June 2024Another U.S. patent was granted, further strengthening our coverage of concentrated formulations of furosemide.
July 2024The application was accepted for filing by the FDA.
August 9, 2024The company announced the approval of our supplemental drug application expanding the FUROSCIX indication in heart failure on August 9, 2024 to include NYHA Class IV heart failure patients.
August 9, 2024The company entered into a Credit Agreement and Guaranty (the 'Credit Agreement').
August 9, 2024The company also entered into a Revenue Participation Right Purchase and Sale Agreement (the 'Revenue Purchase and Sale Agreement').
August 13, 2024The company completed an underwritten public offering of shares of its common stock with net proceeds of $ 53.5 million.
August 2024Positive data from the PK/PD study was announced.
October 7, 2024The company was notified that the FDA awarded 3-year exclusivity to FUROSCIX.
March 6, 2025The FDA approved FUROSCIX for the treatment of edema due to fluid overload in adult patients with chronic kidney disease (CKD).
March 31, 2025The company may borrow $25.0 million (the Tranche B Loan and, together with the Tranche A Loan, collectively, the Term Loan) that we may borrow in a single borrowing on or prior to March 31, 2026.
April 2025The company commenced the product launch for the expanded indication.
Third Quarter 2025The company is targeting a sNDA submission for the autoinjector.
October 7, 2025As a result, the FDA may not approve a subsequent product for subcutaneous administration of furosemide for 3 years from the date of approval of FUROSCIX, or October 7, 2025.
August 9, 2029The Term Loan has a maturity date of August 9, 2029 (the Maturity Date).

Keywords

FUROSCIX, scPharmaceuticals, revenue, CKD, heart failure, autoinjector, FDA approval, financial results, edema, diuresis

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.